SERAHIGH SIGNALFINANCIAL10-K

SERA's operating cash flow deteriorated substantially while the company raised significant capital, reflecting intensified cash burn amid continued R&D investment.

The meaningful deterioration in operating cash flow signals accelerating cash consumption, which is concerning for a company still developing commercial products. However, the substantial increase in stockholders' equity suggests successful capital raising that provides runway for operations, though this dilutes existing shareholders.

Comparing 2026-03-18 vs 2025-03-19View on EDGAR →
FINANCIAL ANALYSIS

SERA's financial position shows mixed signals with operating cash flow burning substantially more cash year-over-year, indicating higher operational expenses despite a modest reduction in R&D spending. The company appears to have raised significant capital, boosting total assets by 40% and stockholders' equity by 58%, providing financial cushion. The reduction in current assets alongside higher total assets suggests the capital raise included longer-term investments or restricted funds.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-80.6%
-$14.2M-$25.6M

Operating cash flow fell 80.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
-67.9%
$28K$9K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Accounts Receivable
Balance Sheet
-64.7%
$34K$12K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
+57.7%
$47.8M$75.4M

Equity base grew 57.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+40.5%
$72.6M$101.9M

Asset base grew 40.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
-14.3%
$47.6M$40.8M

Current assets declined 14.3% — monitor working capital adequacy and short-term liquidity.

R&D Expense
P&L
-10.6%
$14.7M$13.2M

R&D spending cut 10.6% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-19
ADDED
As of March 13, 2026 , the registrant had 38,176,089 and 967,759 shares of Class A and B common stock, $0.0001 par value per share, outstanding, respectively.
Form 10-K Summary 131 Signatures 132 Sera, PreTRM, PreTRM Global, The Pregnancy Company, Sera Prognostics, LikeMine, and our logo are our trademarks.
Our vision is to become the global leader in high-value women s health diagnostics.
We plan to do this by taking a holistic approach to providing pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother s pregnancy journey, improve maternal and neonatal health, and reduce health care costs.
The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, making the longest stretch of the lowest grade in Report Card history.
+7 more — sign up free →
REMOVED
As of March 14, 2025, the registrant had 36,695,803 and 967,759 shares of Class A and B common stock, $0.0001 par value per share, outstanding, respectively.
Form 10-K Summary 129 Signatures 130 Sera, PreTRM, The Pregnancy Company and our logo are our trademarks.
Our vision is to deliver pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother s pregnancy journey, improve maternal and neonatal health, and reduce health care costs.
In many cases these complications have profound short- and long-term health consequences for the mother and baby.
These health consequences of preterm birth alone are estimated to be approximately $25 billion annually in the United States.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →